

Atty. Dkt. No. 040388-0131

U S. Serial No. 10/539,407

RECEIVED
CENTRAL FILE CENTER
SEP 27 2006

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application:

1. (Currently Amended) Use of A method for treating deafness in a subject, comprising administering to said subject a pharmaceutical composition that comprises (a) at least one kinase inhibitor for making drugs for or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable carrier, in an amount effective for inducing differentiation of supernumerary hair cells and Deiters' cells in the developing an organ of Corti for treating deafness of said subject.
2. (Currently Amended) The use method of claim 1, wherein said kinase inhibitor is selected in the group comprising purine derivatives a purine derivative.
3. (Currently Amended) The use method of claim 2, wherein said purine derivatives are derivative is selected in from the group comprising consisting of roscovitine, indirubins and purvalanols- indirubin and purvalanol.
4. (Currently Amended) The use method of claim 1, wherein said kinase inhibitors are inhibitor is administered parenterally, rectally, topically, transdermally or orally.
5. (Currently Amended) The use method of claim 4, wherein said kinase inhibitors are inhibitor is administered by the oral or by injectable route.
6. (Currently Amended) The use method of claim 5, wherein said kinase inhibitors are under inhibitor is in the form of a lozenge lozenges, a compressed tablet compressed tablets, a pill pills, a tablet tablets, a capsule capsules, drops, a syrup syrups, a suspension suspensions or an emulsion emulsions.
7. (Currently Amended) The use method of claim [[4]] 1, wherein the said pharmaceutical compositions comprise composition comprises 100 to 1000 mg of active principle said kinase inhibitor or said salt per dose unit, preferably 300 to 600 mg.

Atty. Dkt. No. 040388-0131
U.S. Serial No. 10/539,407

8. (Currently Amended) The use method of claim 5, wherein said kinase ~~inhibitors are~~ inhibitor is administered under in the form of an injectable solutions solution for ~~the an~~ intravenous, ~~a~~ subcutaneous or an intramuscular route, formulated from a sterile or a sterilizable solution solutions, or ~~under in~~ the form of a suspension suspensions or an emulsion emulsions.
9. (Currently Amended) The use method of claim 8, wherein said injectable ~~forms comprise~~ solution comprises 100-1000 mg of said ~~compound~~ kinase inhibitor or a ~~pharmaceutically~~ acceptable said salt thereof preferably 300 to 600, per dose unit.
10. (Canceled)
11. (New) The method of claim 7, wherein said pharmaceutical composition comprises 300-600 mg of said kinase inhibitor or said salt per dose unit.
12. (New) The method of claim 9, wherein said injectable solution comprises 300-600 mg of said kinase inhibitor or said salt.
13. (New) The method of claim 1, wherein said salt is an acid addition salt.
14. (New) The method of claim 13, wherein said acid is selected from the group consisting of acetic acid, ascorbic acid, maleic acid, phosphoric acid, salicylic acid and tartaric acid.